Is It Too Late to Buy Eli Lilly?
It is hard to explain how impressive Eli Lilly's (NYSE: LLY) GLP-1 success has been. In 2025, sales of the company's Mounjaro and Zepbound rose 99% and 175%, respectively. The two drugs have grown so rapidly that they now account for 56% of Eli Lilly's revenues.
There's likely to be more growth ahead, too, as demand for these weight loss drugs remains strong. However, it may still be too late for you to buy Eli Lilly. Here's why.
The interesting thing about Mounjaro and Zepbound is that they weren't the first GLP-1 weight loss drugs to hit the market. Novo Nordisk (NYSE: NVO) was first to market with Wegovy. However, Eli Lilly's drugs proved to be more effective and quickly took the lead in the new drug category. That's an important fact to keep in mind because it underscores the pharmaceutical sector's competitiveness.
Source Fool.com
